Abstract
Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, lack of consistent manufacturing practices and quality standards, fear of adulteration, and perceived deficiencies in scientific validation of efficacy and safety impede worldwide acceptance of TCM. In addition, Western pharmaceutical industries and regulatory agencies are partial toward single ingredient drugs based on synthetic molecules, and skeptical of natural product mixtures. This review concentrates on three examples of TCM-derived pharmaceuticals and functional foods that have, despite these usual obstacles, risen to wide acceptance in the West based on their remarkable performance in recent scientific investigations. They are: Sweet wormwood (Artemisia annua), the source of artemisinin, which is the currently preferred single compound anti-malarial drug widely used in combination therapies and recently approved by US FDA; Thunder god vine (Tripterygium wilfordii) which is being developed as a botanical drug for rheumatoid arthritis; and green tea (Camellia sinensis) which is used as a functional beverage and a component of dietary supplements.
Keywords: Artemisia annua, artemisinin, Camellia sinensis, (-)-epigallocatechin-3-gallate (EGCG), functional foods, nutraceuticals, traditional Chinese medicine (TCM), tripdiolide, Tripterygium wilfordii, triptolide
Current Drug Discovery Technologies
Title: Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods
Volume: 7 Issue: 1
Author(s): Rocky Graziose, Mary Ann Lila and Ilya Raskin
Affiliation:
Keywords: Artemisia annua, artemisinin, Camellia sinensis, (-)-epigallocatechin-3-gallate (EGCG), functional foods, nutraceuticals, traditional Chinese medicine (TCM), tripdiolide, Tripterygium wilfordii, triptolide
Abstract: Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, lack of consistent manufacturing practices and quality standards, fear of adulteration, and perceived deficiencies in scientific validation of efficacy and safety impede worldwide acceptance of TCM. In addition, Western pharmaceutical industries and regulatory agencies are partial toward single ingredient drugs based on synthetic molecules, and skeptical of natural product mixtures. This review concentrates on three examples of TCM-derived pharmaceuticals and functional foods that have, despite these usual obstacles, risen to wide acceptance in the West based on their remarkable performance in recent scientific investigations. They are: Sweet wormwood (Artemisia annua), the source of artemisinin, which is the currently preferred single compound anti-malarial drug widely used in combination therapies and recently approved by US FDA; Thunder god vine (Tripterygium wilfordii) which is being developed as a botanical drug for rheumatoid arthritis; and green tea (Camellia sinensis) which is used as a functional beverage and a component of dietary supplements.
Export Options
About this article
Cite this article as:
Graziose Rocky, Ann Lila Mary and Raskin Ilya, Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods, Current Drug Discovery Technologies 2010; 7 (1) . https://dx.doi.org/10.2174/157016310791162767
DOI https://dx.doi.org/10.2174/157016310791162767 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry 3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists
Medicinal Chemistry Immunological Aspects of the Complex Regional Pain Syndrome (CRPS)
Current Pharmaceutical Design Psoriatic Arthritis and Risk of Vertebral Fracture: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of Mutual Prodrugs of Carboxylic Group Containing Some Non-Steroidal Anti-Inflammatory Drugs and Propyphenazone
Current Drug Delivery Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Prodrug Designing of NSAIDs
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Modern Therapeutic Antibody Drug Discovery Technologies)
Current Drug Discovery Technologies Potential Role of Bioactive Lipids in Rheumatoid Arthritis
Current Pharmaceutical Design Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis
Current Pharmaceutical Design COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Sexual Dysfunction among Women with Connective Tissue Disease
Current Rheumatology Reviews Pathophysiology and Prevention of Bronchopulmonary Dysplasia
Current Pediatric Reviews Macrophage Dysfunctions in Cystic Fibrosis Pulmonary Disease: Implications in Inflammation and Chronic Infections
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology